Does trastuzumab ( Herceptin ) enhance class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes?
These results suggested that Herceptin treatment might enhance the class I-restricted presentation of endogenous HER-2 antigen via the proteasome step, resulting in higher susceptibility of HER-2-overexpressing tumors to lysis by the HER-2-specific CTLs.
Consumption of MLCT may reduce body weight, body fat and blood TG in hypertriglyceridemic subjects under an appropriate dietary regime.